XT
TCRX icon

XTX Topco’s TScan Therapeutics TCRX Stock Holding History

XTX Topco’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.3K Sell
60,720
-158,281
-72% -$169K ﹤0.01% 3259
2025
Q4 		$219K Buy
219,001
+201,375
+1,142% +$291K 0.01% 2329
2025
Q3 		$32.1K Buy
+17,626
New +$31.2K ﹤0.01% 2250
2024
Q4 		– Sell
-22,438
Closed -$112K – 2919
2024
Q3 		$112K Buy
+22,438
New +$135K 0.01% 1590

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

XTX Topco's TCRX Position: Q1 2026 in Review

XTX Topco reduced its TScan Therapeutics (TCRX) stake by 72% in Q1 2026, selling an estimated $169K and leaving 60,720 shares worth $61.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3259.

XTX Topco first reported a position in TCRX in Q3 2024 and has held it in 4 quarters since. The position peaked at $219K in Q4 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • XTX Topco held 60,720 shares of TScan Therapeutics worth $61.3K as of Q1 2026.
  • XTX Topco sold 158,281 TScan Therapeutics shares in Q1 2026, an estimated $169K.
  • TScan Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3259 holding.
  • XTX Topco first reported a position in TScan Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • XTX Topco's TScan Therapeutics position peaked at $219K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.